Inhibikase Therapeutics Says FDA Grants Orphan Drug Designation To Its Lead Product Candidate IKT-001, Prodrug Of Imatinib Mesylate, For Treatment Of PAH
Inhibikase Therapeutics Inc IKT
$2.18
▼ -4.39%
($-0.10)
⬇️ Below Yest. Low
🗓️ Earnings Next Week
Open
$2.27
Prev Close
$2.28
Day Range
$2.13 – $2.29
52W Range
$1.33 – $2.53
Market Cap
$287.83M
Beta
0.97
EPS (TTM)
$-1.15
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-12-23 |
| Shares Out. | 157,030,000 |
| Website | inhibikase.com/ ↗ |
| Phone | 13022953800 |
| Employees | 35 |
| Net Income | -$16.4M |
| Free Cash Flow | -$35.7M |
| Total Assets | $173.3M |
| Total Liabilities | $5.7M |
| Equity | $167.6M |
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Inhibikase Therapeutics Inc is a publicly traded company under the ticker symbol IKT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)